United Nations: As a decision is expected on the list of emergency uses in the manufacture of COVAXINE in India, a senior WHO has declared the process of carefully evaluating a vaccine to be used and recommending the Recommend sometimes takes time, but you have to ensure. That good advice is given to the world “even if it takes another week or two”.

The World Health Organization “is very clear that we want all countries to recognize vaccines who have received a list of emergency use (EU) through the WHO Council process. But it is also very It is important that WHO, when it makes a recommendation as this, makes that, on a global scale, “said Mike Ryan Director of Health Emergencies.

Ryan answered a question at a recent Q & A referred to if there will be a definitive answer on Covaxin EU before October 26.

The Soumya Swaminathan scientific WHO stated in a tweet earlier that the WHO Technical Advisory Group will meet on October 26 to review the Emergency Use List for the Manufacture of Covaxine manufactured by India Bharat Biotech .

Earlier this week, the World Health Organization had stated in a tweet that it expects additional information from Bharat Biotech regarding Covaxin.

“We are aware that many people expect the WHO recommendation for Covaxin to be included in the emergency use list # COVID19, but we can not cut the corners – before recommending a product for use Emergency, we need to assess it thoroughly to ensure that it is safe and efficient, “who said.

“Bharat Biotech – the Manufacturer of Covaxin – has submitted data to WHO to the rolling and experts of WHO who examined this data. Who expects additional information from the company today,” he said.

Ryan said “we must be absolutely safe” and it is really important that “we collect all the necessary information not only on the vaccine itself, but on the manufacturing processes and all this, because we recommend to the world that this Vaccine is safe, efficient and produced using the highest quality standards. “

Explaining more about how the WHO Technical Advisory Group works, he said vaccine manufacturers must first ask and react and say they want their vaccines to be put in place of TUL, then provide Documentation throughout the process – efficiency studies and manufacturing process.

“Sometimes this requires visits to review and review manufacturing practices and all that must meet in a case presented in this consultative group mechanism, and then it is about there that can make a recommendation,” said Ryan. .

He pointed out that the whole process, even if people can not see it “day by day” is “very measured” because “we must say in the world ‘we have examined it with care, we examined each data room, we examined the entire production cycle and we can say with our hands on our hearts, after considering all this data, here is a safe, efficient and well-produced product that you are our Member State or you as A citizen of the world can take confidence.

“It’s very very important and it sometimes takes more time and it’s frustrating. And it is particularly frustrating if you have had some vaccine that is not recognized by another country and you can not travel. It becomes a problem, “said Ryan.

He stated that the work done by the advisory group and its members were of the highest quality and “it takes time to do it”.

“This is an extremely important task. It is extremely involved and measured and the results of this process have been of very high quality, through this pandemic. And if it takes another week or two, that’s what we will have to take for the file to be complete so that the committee has a chance to look at that and then make the right determination and give good advice to the world, Ryan said.

He added that the Emergency Committee of the International Health Regulations was “very, very clear” and that countries were informed that vaccination certification should not be used as the only measure and means of restricting travel.

“We have other ways to make safe trips, including tests, serological tests, and we believe very strongly that the use of vaccination status because the only travel parameter creates double inequality because countries Who do not have access to vaccines, then de facto have no access to travel either. And it’s a double inequality, “said Ryan.

Bharat Biotech had submitted the IOO (expression of interest) on April 19 for his vaccine. WHO stated that it has started launching vaccine data on July 6, July 6th allows WHO to start its review immediately because the information continues to enter, accelerate the overall review process .

The Covaxin of Bharat Biotech and the Oxford University Cuvischield are the two largely used vaccines in India.

Which stated that the calendar of its EU procedure depends on the speed with which a company producing the vaccine is able to provide the required data